ClinicaliQ Trial Snapshot
- BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1) — Active Not Recruiting • NCT04982393.
- Study tracking disease progression and lumasiran treatment outcomes in primary hyperoxaluria type 1 patients over time.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran. Conditions: Primary Hyperoxaluria Type 1 Lead Sponsor: Alnylam Pharmaceuticals Planned Enrollment: 207 participants